Biomarkers for Early Detection of Clinically Relevant Prostate Cancer: A Multi-Institutional Validation Trial

@inproceedings{Lin2015BiomarkersFE,
  title={Biomarkers for Early Detection of Clinically Relevant Prostate Cancer: A Multi-Institutional Validation Trial},
  author={Daniel Yanfeng Lin},
  year={2015}
}
Abstract : For men diagnosed with early stage prostate cancer a critical need exists for molecular assays that accurately distinguish aggressive prostate cancer from those cancers that will not cause harm if left untreated. In this project, we are assessing three different panels of established molecular biomarkers for their ability to distinguish aggressive cancers from indolent cancers. We have established agreements with three commercial companies to analyze their biomarker platforms in our… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…